Evidence map›Paper›PMID 25315847›Full record

ArticleBMC cancer2014

Racial differences in mantle cell lymphoma in the United States.

Yu Wang, Shuangge Ma

Abstract read
In one paragraph

Article in BMC cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review.Blood and lymphatic cancer : targets and therapy · 2023
    Review
  4. Review
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes.Therapeutics and clinical risk management · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yu Wang
Shuangge MaSchool of Public Health, Yale University, 60 College ST, New Haven, CT 06520, USA. shuangge.ma@yale.edu.

Funding

Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0M
Yale University Clinical and Translational Science Award ProgramUL1TR000142 · NCATS · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2012 to 2015
$31.8M
Novel Methods for Integrative Analysis of Cancer Genomic DataR01CA142774 · NCI · YALE UNIVERSITY · PI MA, SHUANGGE · 2010 to 2013
$1.3M
Robust rank-based methods and detection of GXE in cancer etiology and survivalR21CA165923 · NCI · YALE UNIVERSITY · PI MA, SHUANGGE, ZHANG, YAWEI · 2012 to 2014
$421k
NCATS NIH HHS UL1 TR000142NCI NIH HHS CA142774NCI NIH HHS CA165923NCI NIH HHS R01 CA142774NCI NIH HHS R21 CA165923
6 · The paper itself

Abstract

backgroundMCL (mantle cell lymphoma) is a rare subtype of NHL (non-Hodgkin lymphoma) with mostly poor prognosis. Different races have different etiology, presentation, and progression patterns.

methodsData were analyzed on MCL patients in the United States reported to the SEER (Surveillance, Epidemiology, and End Results) database between 1992 and 2009. SEER contains the most comprehensive population-based cancer information in the U.S., covering approximately 28% of the population. Racial groups analyzed included non-Hispanic whites, Hispanic whites, blacks, and Asians/PIs (Pacific Islanders). Patient characteristics, age-adjusted incidence rate, and survival rate were compared across races. Stratification by age, gender, and stage at diagnosis was considered. Multivariate analysis was conducted on survival.

resultsIn the analysis of patients' characteristics, distributions of gender, marital status, age at diagnosis, stage, and extranodal involvement were significantly different across races. For all three age groups and both male and female, non-Hispanic whites have the highest incidence rates. In the analysis of survival, for cancers diagnosed in the period of 1992-2004, no significant racial difference is observed. For cancers diagnosed in the period of 1999-2004, significant racial differences exist for the 40-64 age group and stage III and IV cancers.

conclusionsRacial differences exist among MCL patients in the U.S. in terms of patients' characteristics, incidence, and survival. More extended data collection and analysis are needed to more comprehensively describe and understand the racial differences.

Indexed as

EthnicityAgedAged, 80 and overFemaleHumansIncidenceLymphoma, Mantle-CellMaleMiddle AgedNeoplasm StagingPopulation SurveillanceSEER ProgramSurvival AnalysisUnited States

Identifiers

PMID25315847
PMCPMC4210548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.